Anti-Endothelin A Receptor

Endothelin A (ET-1) and its receptor, ETAR, play a crucial role in regulating vascular tone, inflammation, and cell proliferation. Dysfunction in this system contributes to endothelial damage, vascular inflammation, and fibrosis. 

Anti-Endothelin A Receptor (Anti-ETAR) autoantibodies disrupt ETAR function, potentially leading to serious complications such as systemic sclerosis, pulmonary arterial hypertension (PAH), and kidney disease. 

Testing for Anti-ETAR can help identify at-risk patients, enabling early intervention and tailored treatment to prevent disease progression and improve patient outcomes.

What is Endothelin A and its Receptor (ETAR)?

Endothelin A (ET-1) is a potent vasoactive peptide produced by endothelial cells that plays a critical role in regulating vascular tone, promoting vasoconstriction, and influencing cell proliferation and inflammation. 

The Endothelin A receptor (ETAR) is a G-protein-coupled receptor on the surface of vascular smooth muscle cells that binds to ET-1, mediating its effects on blood vessels and other tissues. ETAR maintains vascular homeostasis and regulates responses to injury or stress. 

Dysregulation of ETAR signaling, often due to the presence of autoantibodies like Anti-ETAR, can contribute to endothelial dysfunction, vascular inflammation, and fibrotic processes in conditions such as systemic sclerosis, pulmonary arterial hypertension, and kidney disease.

What is Anti-Endothelin A Receptor (Anti-ETAR)?

Anti-Endothelin A Receptor (Anti-ETAR) is an autoantibody targeting the Endothelin A receptor (ETAR), a key protein regulating vascular tone and inflammation. By disrupting ETAR function, Anti-ETAR antibodies contribute to endothelial dysfunction, vascular inflammation, and fibrosis. 

This biomarker is particularly relevant in conditions such as systemic sclerosis, pulmonary arterial hypertension, chronic kidney disease, and kidney transplant rejection. Elevated Anti-ETAR levels are associated with vascular damage and renal dysfunction, while low or negative levels suggest minimal autoimmune activity affecting the Endothelin A receptor.

Who Should Get Tested for Anti-Endothelin A Receptor?

The following groups of people may benefit from anti-endothelin A receptor testing:

Patients with Autoimmune Diseases

Individuals with autoimmune conditions such as systemic sclerosis or lupus should consider Anti-ETAR testing. For these patients, elevated Anti-ETAR levels may indicate disease progression or complications like vascular damage or pulmonary involvement. 

Early testing may promote optimal management of these conditions, reducing the risk of irreversible damage.

Individuals with Suspected Pulmonary Arterial Hypertension (PAH)

PAH is a serious complication that can occur in lupus or systemic sclerosis. 

Patients with symptoms such as shortness of breath, fatigue, chest pain, or syncope should consider being evaluated with Anti-ETAR testing. Elevated levels may serve as a risk marker for developing PAH, allowing clinicians to intervene before complications worsen.

At-Risk Populations

Patients with a family history of autoimmune diseases, chronic kidney disease, or unexplained vascular symptoms may also be considered for testing. Early detection in these populations can help rule out or confirm autoimmune mechanisms driving vascular damage.

Healthcare Providers Diagnosing Autoimmune or Vascular Disorders

Rheumatologists, nephrologists, and cardiologists can use Anti-ETAR testing to guide diagnosis and monitor treatment outcomes. Testing helps stratify the risk for complications like PAH, enabling personalized patient treatment plans.

Test Procedure and Interpretation

The following section discusses the testing procedure and appropriate interpretation of test results:

Testing Procedure and Preparation Requirements

Anti-ETAR testing is performed through an enzyme-linked immunosorbent assay (ELISA), which detects antibodies against the ETAR protein in serum. Testing requires a blood draw. 

Patients do not need to follow specific preparation guidelines, but clinicians should know that immunosuppressive therapies can influence antibody levels.

Normal Reference Ranges

Normal anti-ETAR levels are typically negative or very low. When interpreting results, always consult the laboratory company for their recommended reference ranges.

Clinical Implications of Elevated Levels

Elevated Anti-ETAR levels suggest endothelial dysfunction, vascular injury, and fibrosis, all of which are commonly seen in systemic sclerosis and PAH. 

High titers may predict complications such as interstitial lung disease, which can worsen the prognosis. 

Early detection allows for timely interventions like immunosuppressants, vasodilators, or targeted biologics, which can help manage disease progression and improve patient outcomes.

Clinical Implications of Decreased Levels

Low or negative Anti-ETAR levels generally indicate minimal autoimmune activity affecting the Endothelin A receptor. 

While negative results can suggest that vascular symptoms are not due to autoimmune causes, they should not entirely rule out autoimmune involvement. Early disease stages or fluctuating antibody levels due to immunosuppressive therapy may result in false negatives, requiring further diagnostic evaluation.

Order Antibody Testing

Click here to compare testing options and order antibody test panels.